BCR-ABL1 fusion is the major therapeutic target for patients with CML and detection of changes in gene expression levels might help in the prognosis and diagnosis of CML [43]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.